Details of the Drug Combinations

General Information of This Drug (ID: DMSAOWQ)

Drug Name

Lactulose DMSAOWQ

Synonyms

Cephulac;Cholac;Heptalac;Enulose;Enulose

Indication

Disease Entry	ICD 11	Status	REF
Constipation	DD91.1	Approved	[1]
Hepatic encephalopathy	DB99.5	Approved	[2]
Ornithine transcarbamylase deficiency	5C50.AY	Approved	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Lactulose + Idarubicin	DCG06ML	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]
Lactulose + Ruxolitinib	DCDB4JA	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[4]
------------------------------------------------------------------------------------

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Lactulose + Rifaximin	DCDAGVV	Rifaximin	Hepatic Encephalopathy	[5]
Lactulose + Metronidazole	DC0F8SH	Metronidazole	Hepatic Encephalopathy	[6]
Nitazoxanide + Lactulose	DC82K09	Nitazoxanide	Hepatic Encephalopathy	[6]
Lactulose + Rifaximin	DC6D8L5	Rifaximin	Hepatic Encephalopathy	[7]
Ondansetron + Lactulose	DCAUJA1	Ondansetron	Motility Disorder of Intestine	[8]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Lactulose FDA Label
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5	ClinicalTrials.gov (NCT00364689) RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
6	ClinicalTrials.gov (NCT02334163) The Effects of Nitazoxanide in Hepatic Encephalopathy
7	ClinicalTrials.gov (NCT01842581) The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
8	ClinicalTrials.gov (NCT03833999) Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea